Статья: Современные данные по фармакологии и клинике отравления гамма-гидроксимасляной кислотой

42. GHB Slated for FDA Approval in 2001. http://www.ceri.com/GHB2001.htm, accessed May 18, 2001.

43. Peripheral and Nervous System Drugs Advisory Committee, notice of meeting. http://www.fda.gov/OHRMS/DOCKETS/98fr/021401a.htm, accessed May 18, 2001.

44. Orphan Drug Status for GHB, http://www.fda.gov/orphan/designat/list.htm, accessed May 18, 2001.

45. Department of Health and Human Services, Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting. Fed Regist 2001;66(93):24391.

46. Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomised comparative study versus benzodiazepine. Alcohol Clin Exp Res 1999;23(10):1596-604.

47. Addolorado G, Castelli E, Stefanini G, Casella G. An open multicenter study evaluating 4-hydroxybutyric acid sodium salt in the medium term treatment of 179 alcohol dependent subjects. Alcohol Alcohol 1996;31(4):341-5.

48. Gallimberti L, Canton G, Gentile N, Ferri M. Gamma-hydroxybutyric ccid for the treatment of alcohol withdrawal syndrome. Lancet 1989;30,2(8666):787-9.

49. Beghe' F, Carpanini MT. Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients. Alcohol 2000;20:223-5.

50. Gessa GL, Agabio R, Carai MA, Lobina C, Pani M, Reali R et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol 2000;20:271-6.

51. Rosen MI, Pearsall HR, Woods SW, Kosten TR. The effects of gamma-hydroxybutyric acid in opioid-dependent patients. J Subst Abuse Treat 1997;14(2):149-54.

52. Rosen MI, Pearsall HR, Woods SW, Kosten TR. The effects of gamma-hydroxybutyric acid in naloxone-precipitated opiate withdrawal. Neuropsychopharmacology 1996;14(3):187-93.

53. Gallimberti L, Schifano F, Forza G, Miconi L, Ferrara SD. Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. Eur Arch Psychiatry Clin Neurosci 1994;244(3):113-4.

54. Gallimberti L, Cibin M, Pagnin P, Sabbion R, Pani PP, Pirastu R et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993;9(1):77-81.

55. Gamma-hydroxybutyrate poisoning. The Medical Letter 1991;33(836):8.

56. Snead OC. Gamma-hydroxybutyric acid seizures bear no relation to core temperature. Epilepsia 1990;31(3):253-8.

57. Hoes MJ, Vree TB, Guelen PJ. Circadian rhythm in plasma concentrations of gamma-hydroxybutyric acid in alcoholics. Int J Addict 1981;16(6):1071-5.

58. Snead OC. Gamma-hydroxybutyrate in the monkey. Effect of intravenous anticonvulsant drugs. Neurology 1978;28(11):1173-8.

59. Hechler V., Ratomponirina C, Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABA B binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther 1977;281(2):753-60.

60. Addolorato G, Caputo F, Capristo E, Gasbarrini G. Diazepam in the treatment of GHB dependence. Br J Psych 2000;177:181.

61. Price G. In-patient detoxification after GHB dependence. Br J Psych 2000;177:181.

62. Catalano MC, Glass JM, Catalano G, Burrows SL, Lynn WA, Weitzner BS. Gamma-butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001;42:1.

63. Yates W, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000;75(4):401-2.

64. Henderson, R., Holmes, C. Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care 1976;4(4):351-4.

65. Cadicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: Teaching new tricks to an old drug? Annals of Emergency Medicine 2001;37(1):99-102.

66. Kaasin V, Nagren K, Hietala J, et. al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's Disease. Neurology 2000 Apr 11;54(7):1482-87.

67. Fujita M, Verhoeff NP, Varrone A, et. al. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000 Jan 10;387(2):179-188.

68. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37(2):147-53.

69. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000;18(1):65-70

70. Pearman K. Cocaine: a review. J Laryng Otol. 1979;93:1191-99.